Trabecular bone morphometry was done on rib samples of beagles with hyperadrenocorticism and adrenal adenomas to evaluate bone loss and the remodeling changes responsible. Beagles diagnosed as having clinical hyperadrenocorticism and those with milder or subclinical hyperadrenocorticism diagnosed on the*basis of adrenal and pituitary lesions at necropsy had increased adrenal and pituitary gland weights. In a group of dogs with adrenal cortical adenomas there was atrophy of remaining cortex, and the combined weight of adrenal glands or pituitary weights were not increased. In dogs with clinical hyperadrenocorticism, mean trabecular bone volume was 25% less than controls (P = 0.10). In both clinical and subclinical hyperadrenocorticism groups, the extent of trabecular surface with unmineralized osteoid matrix and osteoblasts was significantly reduced. There were no changes in resorption surfaces or number of osteoclasts present. No bone changes were seen in dogs with adrenal adenomas. In dogs with hyperadrenocorticism it appeared that decreased bone formation was primarily responsible for the relative osteopenia that developed. Although parathyroid glands were moderately enlarged in those dogs for which weights were available, the bone changes were not those of increased remodeling expected in hyperparathyroidism.
Hyperadrenocorticism, or Cushing's disease, results from increased systemic corticosteroids due to a tumor or hyperplasia of the adrenal cortex, or to a tumor in the pituitary gland producing adrenocorticotrophic hormone (ACTH) which stimulates the adrenal cortex. It is also seen with increasing frequency associated with long-term treatment with corticosteroids to alleviate skin conditions, allergies, arthritis, or immune-mediated disorders. Although hyperadrenocorticism is probably one of the most common causes of generalized osteopenia seen radiographically in dogs,23 there is no literature on the incidence or severity of bone loss. Clinically, there have been observations of spontaneous fractures in hyperadrenocorticism and an increased incidence of intervertebral joint disease (R. W. Norrdin and T. R. Carpenter, unpublished observations) which may be related to the bone loss. It is important to understand the mechanisms responsible for the osteopenia so that control or treatment can be approached rationally.
The basis of bone loss in hyperadrenocorticism has been investigated in people and in laboratory animals given corticosteriods experimentally. Findings are by no means uniform and indicate that there are several important factors in the pathogenesis. Bone loss, or osteopenia, results from a negative balance between bone formation and bone resorption in the ongoing 2 3 process of bone remodeling.'3 The term "bone remodeling" refers to the turnover of bone matrix in which there is resorption of bone by osteoclasts at discrete sites throughout the skeleton and the refilling of these sites by osteoblasts with a newly formed osteoid matrix that later becomes mineralized.I3 In hyperadrenocorticism, histomorphometric studies in humans on indices of bone formation have found them to be normal or increased in e x t e r~t ,~J~, '~ or normal to decreased when fluochrome labels are used to measure actual bone mineralization rate^.^,^ In rabbits12 and rat^^^,^^ there is evidence of decreased formation. Bone resorption in hyperadrenocorticism has been found to be normalI6 or i n c r e a~e d~,~J~ in human patients, increased or decreased in rat^,'^,^^ and decreased in rabbits.I2 Increased resorption in human hyperadrenocorticism may be related to parathyroid hyperplasia from decreased calcium absorption. Increased parathyroid hormone levels are sometimes f~u n d .~J I J~ The variation in these findings indicates a complex pathogenesis in which species differences may be important. Although spontaneous hyperadrenocorticism has not been studied in the dog, experimental studies of corticosteroid administration in young dogs revealed decreased formation and decreased resorption; changes in bone volume were not
The objective of the present study was to document the occurrence and severity of bone loss in 5 spontaneous hyperadrenocorticism in a standardized colony of beagles and to define the remodeling changes in the dog specifically.
Materials and Methods

Selection of cases
Cases were selected from clinical and necropsy records at the Colorado State University Collaborative Radiological Health Laboratory beagle colony which represented a total of 1,379 necropsies. Cases were subdivided into those having clinical signs of hyperadrenocorticism prior to death, "clinical hyperadrenocorticism"; those with no clinical diagnosis but with necropsy lesions consistent with milder hyperadrenocorticism, "subclinical hyperadrenocorticism"; and those with benign adrenal tumors at necropsy, "adrenal adenomas."
Clinical hyperadrenocorticism. The clinical diagnosis of hyperadrenocorticism was based on signs of polydipsia, polyuria, and myasthenia with tarsal and carpal flexion, unsteady gait, and abdominal distension. Hepatomegaly was sometimes appreciable on palpation and exophthalmia was common. The dogs had a short, dry haircoat with symmetrical abdominal alopecia and thin skin that was sometimes hyperpigmented. Affected animals had reduced tolerance to stresses such as extreme heat, cold, or surgery. The duration of the condition was the time from the first notation in the clinical record to date of necropsy. Four dogs diagnosed as having hyperadrenocorticism were subjected to an adrenocorticotrophic hormone (ACTH)-response test that consisted of measuring serum cortisol levels before and at 1 and 3 hours after injection of ACTH (1 .O unit/kg body weight).
Subclinical hyperadrenocorticism. Dogs were considered
to have subclinical hyperadrenocorticism if they had a pituitary tumor and adrenal cortical hyperplasia and/or adenomas at necropsy. These dogs usually had microscopic changes in the skin and liver suggesting hyperadrenocorticism, although clinical evaluation had not led to this diagnosis.
Adrenal adenomas. Dogs in this group had one or more cortical adenomas as confirmed by microscopic evaluation. They did not have pituitary tumors nor any pathology or clinical evidence of hyperadrenocorticism.
Controls. The control group consisted of dogs killed within 6 months of their 1 1 th birthday. These were non-irradiated dogs used as age and sex matched controls in a life span study of the effects of a single low dose of ionizing irradiation. While a number of dogs in the other three groups had received single radiation doses of 7 or 83 rads ("CO) in utero or during early development, the number of irradiated and non-irradiated dogs in each group was of about the same proportion as in the colony generally, so radiation was not considered further as a factor.
In all groups, records were screened for evidence of other disease processes that might also effect bone remodeling. On this basis dogs were eliminated if they had clinical hypothyroidism, thyroid atrophy or thyroid tumors, chronic renal diseaseZ5 or elevated serum creatinine, parathyroid chronic diarrhea,20 or lymphohematopoietic neoplasms.26 Serum calcium, phosphorus, and alkaline phosphatase were determined (Autoanalyzer 11, Technicon Instruments Corporation, Tarrytown, NY) at necropsy for those dogs scheduled for sacrifice. For dogs that had died, the most recent values in the records were used. These were from recent clinical examinations or the last annual physical examination.
Pathological evaluation
Dogs were necropsied and organs weighed as part of a standardized protocol. Body weight and femur length were measured to evaluate body size. Fresh weights were obtained on the pituitary gland and the combined right and left adrenal and thyroid glands. In the controls and some dogs scheduled for sacrifice, the parathyroid glands from one side were dissected out and weighed after fixation.
All tumors in the pituitary and adrenal glands were confirmed histologically. In the adrenal gland, cortical adenomas were distinct masses composed of cords or sheets of welldifferentiated cells closely resembling those of the zona fasciculata or zona reticularis. These masses compressed surrounding cortical tissue and had well-demarcated borders, generally delimited by a prominent, although incomplete, fibrous capsule. Adenomas were generally solitary and several times larger than the 1-2 mm nodules of hyperplasia that were also often found in outer cortical zones. Nodules of hyperplasia were usually multiple and did not cause compression of surrounding tissue. Adrenal nodular hyperplasia was commonly noted in all groups including the controls. Pituitary gland tumors were diagnosed with the same criteria used for adrenal adenomas, with the exception that encapsulation was not usually seen. Pituitary adenomas were most often very small masses about 1-2 mm in diameter (microadenomas). Hyperplastic nodules did not have distinct borders, nor were they compressive.
Bone histomorphometry
A sample of bone was collected at necropsy from the middle of the right ninth rib for trabecular bone histomorphometry. This was embedded in methyl methacrylate and sectioned transversely on a Jung model K microtome. Three 6-pm sections were stained with toluidine blue, pH 2.8. Sections were evaluated by standard point-counting, line intercept techniq~es,'~ and a mean for each parameter was determined from the three sections. The amount of trabecular bone was measured as the trabecular bone volume or percent trabecular bone which was the proportion of the marrow cavity occupied by trabecular bone (Figs. 1, 2) . The percent osteoid volume was the proportion of the trabecular bone volume that was unmineralized osteoid matrix. Trabecular bone surfaces were measured beginning at a line through their base, or cortical attachment, that was determined from the general outline of the marrow cavity. The percent osteoid surface was the proportion of total trabecular surface covered by osteoid matrix (Fig. 3) . The percent osteoblast surface was the proportion of surface covered by plump, active-appearing osteoblasts (Fig. 4 ). The width of osteoid seams and the mean wall thickness were measured directly. The mean wall thickness was the amount of bone formed at a completed bone were measured as formation parameters. Toluidine blue.
remodeling site (i.e,, where there was no longer any bone formation and the surface was covered by flattened lining cells). It was measured as the depth of parallel lamellae from the surface to the cement line. A polarizer was used to aid in this measurement ( Fig. 5) . Resorption parameters were the resorption surface and number of osteoclasts. The percent active or osteoclastic resorption surface was the scalloped surface with osteoclasts in Howship's lacunae, while the percent resting resorption surface was the fraction of trabecular surface with Howship's lacunae that did not contain osteoclasts ( Fig. 6 ). The latter are interpreted as areas where resorption has occurred but there has not yet been refilling of the site with osteoid matrix. The number of osteoclasts were counted and expressed per mm of trabecular bone surface.
Statistical evaluation of the data consisted of analysis of variance and use of Fischer's Least Significant Difference method32 to determine differences between the means for the groups. 
Results
Clinical findings
Dogs were similar in age to the 1 1 -year control group (Table 1 ). There were five females and four males in the control group. The female : male ratio in the other groups were 6:3, 9:2, and 5:7 for the clinical and subclinical hyperadrenocorticism and adrenal tumor groups, respectively. The estimated duration of disease in the clinical hyperadrenocorticism group was 17.8 f 7.8 months (+standard error) with a range of 2 to 75 months. There was a tendency for serum calcium levels to be lower (P = 0.07) in the clinical hyperadrenocorticism group as compared to controls. Serum alkaline phosphatase was not significantly different in any group, nor were any significant differences found in serum cholesterol, glucose, urea nitrogen, or creatinine. In three of four dogs given adrenocorticotrophic hormone (ACTH) there was an elevated resting cortisol level (45-141 ng/ml; normal <40 ng/mlZ8). In all four there was a 2 to 1 1-fold increase in serum cortisol levels at 1 hour (332-414 ng/ml; normal 90-200 ng/m128), and they were still elevated at 3 hours.
Necropsy findings
There was no difference in body weights ( Table 2) . Mean adrenal gland weight for dogs with clinical hyperadrenocorticism was three times that of controls (P < 0.0 1). There was also an increase in adrenal gland weights in the subclinical hyperadrenocorticism group as compared to controls (P < 0.01). Both groups had significantly greater pituitary weights associated with the presence of tumors. Parathyroid gland weights were greater in the clinical hyperadrenocorticism group than in controls (P < 0.0 l), although values were only available for five dogs. Only one value was available for the subclinical group. There was no significant difference in any group in thyroid gland weights or femur length.
Pathological findings
In addition to the typical skin and liver changes, the nine dogs with clinical signs of hyperadrenocorticism had lesions in both adrenal and pituitary glands. Adrenal glands had diffuse cortical hyperplasia in all nine cases; cortical adenomas were also present in four cases. One dog with an adenoma in one gland had an ad- Fig. 7 . Trabecular bone volume expressed as percent of marrow cavity area occupied by bone. Values in the clinical hyperadrenocorticism group were generally lower than controls with the exception of one high value.
enocarcinoma in the contralateral gland that had invaded the postcava. In the pituitary gland, adenomas were found in the pars intermedia in all nine dogs.
Three dogs also had adenomas in the pars distalis in addition to the pars intermedia tumor. A series of these adenomas was shown to contain ACTH with specific immunoperoxidase staining (Dako Corporation, Santa Barbara, CA). The only other lesion notably consistent in the group was pulmonary thrombosis, which was found in four dogs.
In the subclinical hyperadrenocorticism group, adrenal cortical adenomas were present in ten of 1 1 dogs; the other dog had marked diffuse adrenocortical hyperplasia. In pituitary glands, five adenomas were in the pars intermedia and six were in the pars distalis. There were no consistent systemic lesions in this group except for variable, milder skin and liver changes of h yperadrenocorticism.
In 12 dogs with adrenal cortical adenomas, five tumors were bilateral.
Bone histomorphometry
The amount of trabecular bone in the marrow cavity is presented as percent trabecular bone volume (Fig.   7 ). The mean for the control group was 12.76 f 0.77%. The group with clinical hyperadrenocorticism had a mean of 9.82 1-1.50%. One dog in the group had a value (18.96%) above the standard error range of the control group, and the probability of a statistical difference for the clinical hyperadrenocorticism dogs as a group was P = 0.10. The mean values for trabecular bone volume in the subclinical hyperadrenocorticism group (14.18 1-0.58%) and adrenal adenoma group (16.13 f 1.23%) were not significantly different from controls. The clinical hyperadrenocorticism group had a decrease in the proportion of trabecular bone surface covered by unmineralized osteoid (P < 0.01) and osteoblasts (P < 0.05) as compared to controls ( Table   3 ). These dogs also had a reduction in osteoid volume in trabecular bone (P < 0.05) as compared to controls.
Moreover, the mean wall thickness, i.e., the amount of bone in remodeling sites where bone formation is completed, was about 25% less than controls (P < 0.0 1).
The group with subclinical hyperadrenocorticism had reduced osteoid-covered surface (P < 0.0 1) and mean wall thickness (P < 0.05) as compared to controls.
Formation parameters in the adrenal adenoma group were similar to controls.
Although one dog in the clinical hyperadrenocorticism group had a high value for osteoclastic resorption surface (2.60%) and number of osteoclasts per mm surface (0.574), values for the group were not significantly different from controls. No significant differences were found in resorption parameters in any of the other groups ( Table 4 ).
Discussion
Clinical and necropsy findings reported here for beagles with hyperadrenocorticism and adrenal adenomas are similar to those in the literature. 1,5~19,21,22~29 There were more females than males in the clinical hyperadrenocorticism group and subclinical hyperadrenocorticism group. An approximately equal proportion of males and females is usually found in pituitarydependent hyperadrenocorticism and a higher incidence of females in hyperadrenocorticism due to adrenal tumors.29 The reason for the higher incidence in females is unknown.
All beagles with clinical hyperadrenocorticism had pituitary tumors, and this is expected in 85-90% of case^.^.^^ There was a higher proportion of tumors in the pars intermedia than pars distalis, and the reverse is usually f o~n d .~,~~ Dogs with clinical signs had a tendency to lower serum calcium, although normocalcemia is usually seen.21 Elevation of serum alkaline phosphatase, which is c~n s i s t e n t l y~~.~~ although not universally found,'O was not present in either of the groups with hyperadrenocorticism. This is unexplained, although values in these older dogs tended to 7.60 f 1.67
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be high and quite variable. The pulmonary thrombosis found in four clinical hyperadrenocorticism cases has been previously reported5 and is apparently due to a coagulopathy associated with the hormonal imbala n~e .~,~~ Generally, findings in dogs classified as subclinical hyperadrenocorticism were similar but not as marked as those in the clinical hyperadrenocorticism group. They were considered to represent a milder form of the disease. Dogs with adrenal adenomas had no other signs of hyperadrenocorticism at necropsy and no changes in bone histomorphometry that might represent a longstanding subtle hyperadrenocorticism. Adenomas can be the cause of hyperadrenocorticism in 10-1 5% of cases,29 but in this group of dogs, in which tumors were usually 1 cm or less in diameter, there was apparently secondary atrophy of the uninvolved cortex, so that total adrenal gland weights were not increased.
Bone studies indicate that there was approximately 25% less trabecular bone in dogs with frank clinical signs of hyperadrenocorticism. One dog with a higher value prevented the difference from being significant at less than P = 0.10. No justification could be found in the records to delete this outlyer. The proportion of the decrease in the dogs is somewhat less than the 35-50% decrease found in human hyperadrenocorticism.8J6 This may be attributable to the duration of the condition, which was estimated at 18 months in our dogs as opposed to 1 to 5 years for human pat i e n t~.~,~~ Studies in human patients have shown that bone loss is earlier3' and greaterI5 in trabecular bone than in cortical bone, and changes are essentially the same whether due to Cushing's disease or to prolonged corticosteroid admini~tration.~ Significant decreases in osteoblast and osteoid-covered surface and the decreased osteoid volume in the dogs with clinical hyperadrenocorticism indicate that decreased formation was primarily responsible for the bone loss. It should be noted that tetracycline labels were not present in these dogs, and although there is general agreement, discrepancies have been noted between the extent of osteoid-covered surface and dynamic bone formation as measured from tetracycline labeling. 35 Nevertheless, the pattern and consistency of the decreased formation parameters in both hyperadrenocorticism groups indicates this was the most important pathogenetic factor in the bone loss. In studies of hyperadrenocorticism in people, the osteoid-covered surface has been norma18J4 or i n c r e a~e d ,~J~ but the extent or rate of actively mineralizing new bone matrix as measured from double tetracycline labels is normal8 or de~reased.~,'~ In experimental studies involving ratsL7 and rabbits,'* formation surface has been consistently decreased. This was also true in experimental studies in dog^.'^,^^ The mean wall thickness is a measure of the total amount of bone formed at each completed remodeling site. The decrease found in dogs with hyperadrenocorticism indicates less bone formed per site under the influence of corticosteroid excess. Assuming no difference in the depth of erosion sites, this means osteoblasts forming bone at a normal apposition rate ceased formation after a shorter period,8 or osteoblasts working at a slower rate3J6 had not produced as much matrix when they stopped at the end of a normal formation period. This suggests a decreased rate of osteoblastic activity or a decreased lifespan of activity with difficulty in the recruitment of osteoblasts. In vitro studies indicate corticosteroids suppress synthetic activity and interfere with the differentiation of osteoblasts from progenitor celk4z9 Apparently, corticosteroids have a direct effect on the osteoblastic cell pool and cell activity that is at least partly responsible for the decreased bone formation seen in the dogs.
Bone resorption surface and numbers of osteoclasts were not significantly different in any of the groups. One dog in the clinical hyperadrenocorticism group had elevated resorption parameters, but other data from this individual were unremarkable. Human patients with hyperadrenocorticism tend to have a moderate increase in bone resorption p a r a m e t e r~,~~~J~ although the difference is not always significant.16 In experimental animal studies, a decrease has been found in rabbits12 and in rats given higher doses of corticosteroids.I7 An increase in the number of osteoclasts was found in rats given lower doses.I7 In dogs given corticosteroids, a decrease in resorption surface was found which, along with decreased formation surface, suggested a suppression of remodeling a~t i v i t y . '~,~~ These findings indicate that species differences and dosage are important factors in determining resorption effects. When corticosteroids are added in vitro to organ culture models of bone resorption, a decrease in the release of previously administered radiocalcium is seen,3o suggesting the direct effect on the cellular level cell is inhibition.
The increased resorption and increased osteoid surface seen in human studies has led to the investigation of hyperparathyroidism in hyperadrenocorticism. It has been reported that parathyroidectomy in rats eliminates the increase in osteoclasts seen with low dose cortico~teroids,~~ suggesting the bone resorption is mediated by parathyroid hormone. Hyperparathyroidism is thought to be secondary to hypocalcemia from corticosteroid-induced suppression of intestinal calcium absorption. This may be a direct effect of corticosteroids on intestinal mucosa or interference with the conversion of vitamin D to its active metabolite, 1,25 dihydroxycholecalcifero1.2~4~7 Elevated immunoreactive parathyroid hormone levels have been found in some,I6 but not all," human patients with hyperadrenocorticism and have been shown to be higher in patients on higher doses of cortico~teroids.~ In the present study, parathyroid gland weights were mildly to moderately increased in five of nine dogs with clinical hyperadrenocorticism for which data were available. This indicates parathyroid hyperplasia had played a role at some point in the progression of disease. Parathyroid weights represent an indirect measure of parathyroid activity but have correlated well with changes in bone remodeling parameters in renal secondary hyperparathyroidism in beagle^.^^,^^ Changes in beagles with hyperadrenocorticism indicate that decreased osteoblastic synthesis of new bone matrix is primarily responsible for a moderate osteopenia. The significance of the mild parathyroid gland enlargement is unclear. In dogs with parathyroid or more marked hyperparathyroidism associated with renal there is increased remodeling activity with a greater extent of both resorption and osteoblast and osteoid-covered formation surfaces. If there has been any activation of remodeling in the past, the formation phase has been suppressed by excess corticosteroids. If the decreased formation was due to suppression of remodeling activity, as has been suggested from some experimental s t~d i e s , '~J~,~~ a decrease in resorption would also have been seen, but resorption was normal in dogs with spontaneous hyperadrenocorticism. Additional studies at various stages of disease on the dynamics of bone remodeling and parathyroid activity would be necessary to further clarify the pathogenesis.
